Can 99mTc-DPD scintigraphy track tafamidis response in hATTR cardiac amyloidosis?

Abstract

Introduction

Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a major cause of heart failure, due to improved awareness of red flags and growing use of non-invasive tests such as 99mTC-DPD bone scintigraphy. The emergence of disease-modifying therapies (DMT), particularly tafamidis, have significantly altered the natural history of ATTR-CM and highlighted the need for reliable methods to assess treatment response. However, the ability of imaging modalities to reflect changes in amyloid burden during therapy and track disease progression is not fully established.